How many institutional investors hold NVO?

4 tracked institutional investors disclosed a position in NVO (NOVO-NORDISK A S) in their most recent 13F filing.

Who is the largest institutional holder of NVO?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in NVO, valued at $1.6B.

What sector is NVO in?

NOVO-NORDISK A S is classified in the Health Care GICS sector, Drug Manufacturers industry.

Where does this NVO ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

NVO — NOVO-NORDISK A S

Name: NOVO-NORDISK A S (NVO) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Health Care · Drug Manufacturers

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About NOVO-NORDISK A S (NVO)

NOVO-NORDISK A S (NVO) appears in the most recent 13F filings of 4 tracked institutional investors. NOVO-NORDISK A S is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.6B. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NVO

100

/100

Strong Institutional Accumulation

Added / Increased1

Reduced0

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track NVO

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

NVO Ownership Composition

How NOVO-NORDISK A S is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

93% of tracked value

Institutions

tracked investors

Total Reported

$924.5M

combined 13F value

Other92.9%
Hedge Funds7.1%

Other(3)

92.9%

Hedge Funds(1)

7.1%

Tracked investors reporting NVO

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	20.1M	$740.1M	0.12%	Mar 31, 2026
Izzy Englander	Millennium Management	3M	$111.2M	0.05%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	1.8M	$65.5M	0.08%	Mar 31, 2026
Ray Dalio	Bridgewater Associates	138.9K	$7.7M	0.10%	Sep 30, 2025

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
20.1M
Value
$740.1M
% Portfolio
0.12%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
3M
Value
$111.2M
% Portfolio
0.05%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
1.8M
Value
$65.5M
% Portfolio
0.08%
Ray DalioSep 30, 2025
Bridgewater Associates
Shares
138.9K
Value
$7.7M
% Portfolio
0.10%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Ray Dalio	New	—	$7.7M	Nov 13, 2025

Ray Dalio
New
$7.7MNov 13, 2025

Frequently asked questions

How many institutional investors hold NVO?: 4 tracked institutional investors disclosed a position in NVO (NOVO-NORDISK A S) in their most recent 13F filing.
Who is the largest institutional holder of NVO?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in NVO, valued at $1.6B.
Did institutional ownership of NVO increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 0 fully exited NVO.
What sector is NVO in?: NOVO-NORDISK A S is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this NVO ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.